We are live on ! Find out more
ERNA icon

Eterna Therapeutics
ERNA

11 hedge funds and large institutions have $712K invested in Eterna Therapeutics in 2024 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

0% less ownership

Funds ownership: 0.02% → 0.02% (-0%)

15% less funds holding

Funds holding: 13 → 11 (-2)

27% less capital invested

Capital invested by funds: $982K → $712K (-$270K)

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

Holders
11
Holders Change
-2
Holders Change %
-15.38%
% of All Funds
0.16%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
1
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$2.26K
2
TRCT
Tower Research Capital (TRC)
New York
+$2.26K
3
MA
Montag & Associates
Georgia
+$752

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$24.1K
2
Renaissance Technologies
Renaissance Technologies
New York
-$24K
3
UBS Group
UBS Group
Switzerland
-$1.78K
4
BlackRock
BlackRock
New York
-$1.5K
5
NS
NBC Securities
Alabama
-$1K

ERNA Hedge Fund Activity: Q2 2024 in Review

11 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Eterna Therapeutics (ERNA) for Q2 2024, worth a combined $712K — down 27% from $982K a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of ERNA and 1 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 2 added.

The largest buyer was Geode Capital Management, adding an estimated $2.26K. The largest seller was Citadel Advisors, exiting entirely with an estimated $24.1K sold.

  • 11 institutional investors held Eterna Therapeutics (ERNA) as of Q2 2024, down from 13 in Q1 2024.
  • Funds reported $712K of Eterna Therapeutics stock for Q2 2024, down 27% quarter-over-quarter.
  • 1 fund opened new Eterna Therapeutics positions in Q2 2024 and 3 closed out, a net change of -2 holders.
  • The largest Eterna Therapeutics buyer in Q2 2024 was Geode Capital Management, an estimated $2.26K added.
  • The largest Eterna Therapeutics seller in Q2 2024 was Citadel Advisors, an estimated $24.1K sold.

Based on aggregated 13F filings for Q2 2024.